Collaboration aims to accelerate the development of treatments for chronic kidney disease (CKD) and other conditions Rectify ...

Rectify Pharmaceuticals has entered a strategic research and licensing agreement with Boehringer Ingelheim to accelerate the ...

Boehringer Ingelheim has opened another front in its attack on chronic kidney disease (CKD), offering Rectify Pharmaceuticals up to $448 million to partner on a preclinical program.

Edwards Lifesciences today announced the company's SAPIEN M3 mitral valve replacement system is the first transcatheter therapy utilizing a transseptal approach to receive U.S. Food and Drug ...

Many uterine fibroids go undiagnosed due to a lack of symptoms (e.g., heavy menstrual bleeding, dysmenorrhea, pelvic pressure, urinary frequency), resulting in an unknown true incidence and prevalence ...

In this Tools of the Trade article, Rukshan Ahamed Mohamed Rafeek and Natkunam Ketheesan describe the utility of the Lewis rat autoimmune valvulitis model in assessing potential therapeutic ...

Baystreet.ca News Commentary – The longevity economy is entering a massive repricing event as researchers confirm that ...

Clinicians discuss the rapidly evolving therapies, technology, and surgical approaches for early-stage NSCLC and take a fresh look at the future of care. Teamwork: A Multidisciplinary Approach to ...